References
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:https://doi.org/10.3322/caac.20107
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:https://doi.org/10.3322/caac.21208
- Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31(35):4438–4444. doi:https://doi.org/10.1200/JCO.2012.48.5805
- Wilke H, Muro K, Van Cutsem E, Oh S-C, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim T-Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–1235. doi:https://doi.org/10.1016/S1470-2045(14)70420-6
- Ock C-Y, Oh D-Y, Lee J, Kim T-Y, Lee K-H, Han S-W, Im S-A, Kim T-Y, Bang Y-J. Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. Gastric Cancer. 2016;19(2):597–606. doi:https://doi.org/10.1007/s10120-015-0481-4
- Takayoshi K, Uchino K, Nakano M, Ikejiri K, Baba E. Weight loss during initial chemotherapy predicts survival in patients with advanced gastric cancer. Nutr Cancer. 2017;69(3):408–415. doi:https://doi.org/10.1080/01635581.2017.1267774
- Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, et al. Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment for advanced gastric or gastroesophageal junction cancer. Mol Cancer Ther. 2017;16(10):2215–2222. doi:https://doi.org/10.1158/1535-7163.MCT-16-0895
- Blum D, Omlin A, Baracos VE, Solheim TS, Tan BHL, Stone P, Kaasa S, Fearon K, Strasser F. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol. 2011;80(1):114–144. doi:https://doi.org/10.1016/j.critrevonc.2010.10.004
- Omlin A, Blum D, Wierecky J, Haile SR, Ottery FD, Strasser F. Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study. J Cachexia Sarcopenia Muscle. 2013;4(1):55–61. doi:https://doi.org/10.1007/s13539-012-0099-x
- Lu Z, Yang L, Yu J, Lu M, Zhang X, Li J, Zhou J, Wang X, Gong J, Gao J, et al. Change of body weight and macrophage inhibitory cytokine-1 during chemotherapy in advanced gastric cancer: what is their clinical significance? PLoS One. 2014;9(2):e88553. doi:https://doi.org/10.1371/journal.pone.0088553
- Kanagavel D, Pokataev IA, Fedyanin MY, Tryakin AA, Bazin IS, Narimanov MN, Yakovleva ES, Garin AM, Tjulandin SA. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol. 2010;21(9):1779–1785. doi:https://doi.org/10.1093/annonc/mdq032
- Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34(4):503–509. doi:https://doi.org/10.1016/S0959-8049(97)10090-9
- Sanchez-Lara K, Ugalde-Morales E, Motola-Kuba D, Green D. Gastrointestinal symptoms and weight loss in cancer patients receiving chemotherapy. Br J Nutr. 2013;109(5):894–897. doi:https://doi.org/10.1017/S0007114512002073
- Bosaeus I, Daneryd P, Svanberg E, Lundholm K. Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer. 2001;93(3):380–383. doi:https://doi.org/10.1002/ijc.1332
- Cao D-x, Wu G-h, Zhang B, Quan Y-j, Wei J, Jin H, Jiang Y, Yang Z-a. Resting energy expenditure and body composition in patients with newly detected cancer. Clin Nutr. 2010;29(1):72–77. doi:https://doi.org/10.1016/j.clnu.2009.07.001
- Joo EH, Rha SY, Ahn JB, Kang HY. Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer. Support Care Cancer. 2011;19(7):971–978. doi:https://doi.org/10.1007/s00520-010-0917-7
- Kang JH, Lee SI, Lim DH, Park K-W, Oh SY, Kwon H-C, Hwang IG, Lee S-C, Nam E, Shin DB, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30(13):1513–1518. doi:https://doi.org/10.1200/JCO.2011.39.4585
- Naito T. Evaluation of the true endpoint of clinical trials for cancer cachexia. Asia Pac J Oncol Nurs. 2019;6(3):227–233. doi:https://doi.org/10.4103/apjon.apjon_68_18
- Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut. 2005;54(4):540–545. doi:https://doi.org/10.1136/gut.2004.047563
- Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335–345. doi:https://doi.org/10.1016/S1470-2045(13)70055-X
- Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista G, Barazzoni R, Blaauw R, Coats AJS, et al. GLIM criteria for the diagnosis of malnutrition - a consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle. 2019;10(1):207–217. doi:https://doi.org/10.1002/jcsm.12383
- Yoon SL, Kim JA, Kelly DL, Lyon D, George TJ Jr. Predicting unintentional weight loss in patients with gastrointestinal cancer. J Cachexia Sarcopenia Muscle. 2019;10(3):526–535. doi:https://doi.org/10.1002/jcsm.12398
- Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, Strasser F, Thoresen L, Jagoe RT, Chasen M, et al. Diagnostic criteria for the classification of cancer-associated weight loss. JCO. 2015;33(1):90–99. doi:https://doi.org/10.1200/JCO.2014.56.1894
- Parr CL, Batty GD, Lam TH, Barzi F, Fang X, Ho SC, Jee SH, Ansary-Moghaddam A, Jamrozik K, Ueshima H, et al. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424,519 participants. Lancet Oncol. 2010;11(8):741–752. doi:https://doi.org/10.1016/S1470-2045(10)70141-8
- Jager-Wittenaar H, Ottery FD. Assessing nutritional status in cancer: role of the Patient-Generated Subjective Global Assessment. Curr Opin Clin Nutr Metab Care. 2017;20(5):322–329. doi:https://doi.org/10.1097/MCO.0000000000000389
- Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495. doi:https://doi.org/10.1016/S1470-2045(10)70218-7
- Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista G, Barazzoni R, Blaauw R, Coats A, et al. GLIM criteria for the diagnosis of malnutrition - a consensus report from the global clinical nutrition community. Clin Nutr. 2019;38(1):1–9. doi:https://doi.org/10.1016/j.clnu.2018.08.002